AstraZeneca supplies UKHSA's live attenuated flu vaccine for 2026/2027
- UK Health Security Agency
- Negotiated procedure without prior publication (above threshold), 1 bid
- 1 August 2026 to 31 July 2028
The UK Health Security Agency (UKHSA) is buying live attenuated influenza vaccine for the 2026/2027 season from AstraZeneca.
UKHSA awarded the contract directly, without a competition. It found that only one supplier could provide the vaccine to the specification and standard it needed, so the market offered no competition.
The £225.4m contract was awarded in June 2026 and is due to end in July 2028. UKHSA can extend it twice, by 12 months each time.
Contract ends July 2028
- What
- Vaccines and immunisation products
- Supplier
- AstraZeneca
- Value
- £225.4m
- How it was bought
- Negotiated procedure without prior publication (above threshold)
- 1 bid
- Dates and next
- Aug 2026 to Jul 2028
- Being re-tendered now